



## News release |

### INTERIM STATEMENT, THIRD QUARTER 2009

Louvain-la-Neuve, Belgium, November 18, 2009 – Embargo until 5:40 p.m. (Belgian time)  
IBA (Ion Beam Applications SA: Reuters IBAB.BR and Bloomberg IBAB.BB)

#### KEY FACTS AND FIGURES

### THIRD QUARTER 2009 IN LINE WITH FIRST AND SECOND QUARTERS

IBA posted the following results for the first nine months of 2009 compared with the same period of last year:

- Sales growth close to 20 percent. On a like-for-like basis (without the acquisition of Cisbio), growth would have been around zero, with a decline in the Equipment segment canceling real growth in Pharmaceuticals.
- Low double-digit growth in recurring operating income.
- Net income down sharply compared to September 2008, reflecting the exceptional strong impact of deferred tax income on 2008 results.

Highlights by business segment:

#### PHARMACEUTICALS

- Sales growth of more than 50 percent for the first nine months: 5 percent internally and the rest from changes in the scope of consolidation (primarily the acquisition of Cisbio).
- Cooperation agreement signed in February 2009 with Eczacibasi-Monrol Nuclear Products AS to develop the market for PET and SPECT radiopharmaceuticals in the Balkans, the Middle East, North Africa, and Central and Eastern Europe. This agreement gives IBA customers a network of 52 PET radiopharmaceutical production and distribution facilities on three continents.
- Signature In May 2009 of a partnership agreement with BV Cyclotron VU, based in Amsterdam, for the production and distribution of PET radiopharmaceuticals labeled with fluorine 18 (<sup>18</sup>F).
- Exclusive cooperation agreement signed in September for the marketing of Aposense<sup>®</sup> [<sup>18</sup>F]-ML-10, Aposense's new imaging agent for the molecular imaging of apoptosis (programmed cell death), which should contribute greatly to early-stage detection of cancer, to monitoring and assessment of response to treatment, as well as to the development of new therapies.



## News release |

### EQUIPMENT

- Sales for the first 9 months of the year in this business segment fell almost 10 percent compared to 2008 due to a sharp drop in orders in 2008 and early 2009. Orders have rebounded in the past several months, heralding the possibility of renewed growth in 2010.
- Profitability in this area improved significantly, thanks to a major productivity initiative and better contract terms.
- Proton therapy:
  - On the heels of a contract for a proton therapy facility in Prague in May 2009, IBA got an order for a proton therapy facility in Trento, Italy, early in the third quarter. The contract should be signed by year-end.
  - Work continued on the building and installation of seven proton therapy centers, with six at the on-site installation stage.
- Accelerators:
  - After a quiet first half-year, sales picked up in the third quarter. On September 30, the Group had 10 orders for industrial cyclotrons and accelerators. However, this does not come close to last year's record of 22 accelerators by the same date.
- Dosimetry:
  - Despite a rocky start this year, this business unit showed slim year-over-year growth at September 30. The second and third quarters benefited from some recovery in hospital capital expenditures and the launch of new products in the second quarter.

### BALANCE SHEET ITEMS

The Group's cash flow was adversely affected by scant orders in the Equipment segment and continued renovation of the Saclay production plant, for which it had received financing from Schering. Despite these factors, its cash flow position remained solid at September 30.



## News release |

### EVENTS SUBSEQUENT TO THE END OF THE REPORTING PERIOD

- **Pharmaceuticals:**
  - On October 5, 2009 IBA announced that the last patient had been tested in the Phase III registration trial for Redectane<sup>®</sup>, a proprietary product for the diagnosis and identification of renal cancer.
  - On October 29, 2009 IBA announced that it had received a positive opinion on Scintimun<sup>®</sup>, a product used in bone scintigraphy.
- **Equipment:**
  - On October 29, 2009 IBA announced the launch of the MaxiPRO renting solution for proton therapy facilities, which will enable more hospitals and cancer centers to make proton therapy available to their cancer patients.
  - On November 1, 2009, at ASTRO, IBA unveiled Compass 2.0, its new patient-specific dosimetry platform which will allow oncologists to verify the dose administered to each patient in order to maximize the effectiveness of rotational radiotherapy treatments.
  - On November 2, 2009 IBA announced the market launch of Proteus Nano, a smaller, lower cost proton therapy facility designed to make this technology more accessible to cancer patients the world over.

### OUTLOOK

Due to the current economic uncertainties, the Group is no longer issuing guidance.

### SHAREHOLDER CALENDAR

Publications of results on December 31, 2009	March 15, 2010
Interim statement, first quarter 2010	May 11, 2010
2010 General Shareholders' Meeting	May 12, 2010 - 10:00 a.m.
Publications of results on June 30, 2010	August 31, 2010
Interim statement, third quarter 2010	November 18, 2010

Pursuant to the Royal Decree of November 14, 2007, IBA declares that this interim statement was prepared by its Chief Executive Officer, Pierre Mottet, and its Chief Financial Officer, Jean-Marc Bothy.



## News release |

### **ABOUT IBA**

Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is primarily active in the medical industry. It develops and markets state-of-the-art equipment and radiopharmaceuticals for cancer diagnosis and treatment. Leveraging its scientific expertise, IBA also provides electron accelerators for industrial sterilization and ionization. IBA is listed on the pan-European stock exchange Euronext and is included in its BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: <http://www.iba-worldwide.com>

### Contact

#### **IBA**

Jean-Marc Bothy

Chief Financial Officer

Telephone: +32 10 47 58 90

[investorrelations@IBA-group.com](mailto:investorrelations@IBA-group.com)